New antiretroviral drugs, part II: NRTIs, NNRTIs, and beyond.

Robert Leo Murphy*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

5 Scopus citations

Abstract

The second installment, of a two-part article on new antiretroviral drugs in development, provides information on five nucleoside and four nonnucleoside reverse transcriptase inhibitors. In addition, two new classes of drugs, fusion inhibitors and integrase inhibitors, are introduced. The results of in vitro and in vivo trials are provided. Researchers hope these new drugs will be more potent, have less cross-resistance, and be better tolerated by HIV-infected patients than current antiretrovirals.

Original languageEnglish (US)
JournalAIDS clinical care
Volume11
Issue number6
StatePublished - Jan 1 1999

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'New antiretroviral drugs, part II: NRTIs, NNRTIs, and beyond.'. Together they form a unique fingerprint.

Cite this